Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IMA402

Bispecific antibody · developed by Immatics Biotechnologies GmbH

Phase 1/2 Most advanced trial
IMTX Developer
1 Registered trials

What is IMA402?

IMA402 is administered by intravenous infusion, alone or together with IMA401, and has been studied in patients with refractory, recurrent or solid tumor cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Therapy area
Oncology
Developer
Immatics Biotechnologies GmbH (IMTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05958121 Phase 1/2 Refractory Cancer Recruiting IMTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CancerRecurrent CancerRefractory CancerSolid Tumor, Adult

More from Immatics Biotechnologies GmbH

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the IMTX page.

Follow IMTX, the company behind IMA402

See IMTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.